Evidation announced on November 12, 2026, that it has completed participant monitoring and biospecimen collection in its Precision in Autoimmune Condition Evidence pilot, known as PACE, an exploratory rheumatoid arthritis study combining symptom-triggered blood sampling with longitudinal digital health information. The approximately 60-day investigation enrolled 29 participants who submitted more than 1,300 daily symptom assessments, providing a foundation for analysing changes in inflammation-associated proteins during baseline, flare and recovery periods.
The pilot represents a methodological development rather than a new diagnostic test or a completed biomarker discovery programme. Evidation intends to examine within-person changes across 251 inflammation-associated proteins, connecting those measurements with symptom reports, wearable observations and clinical history. The company has completed data collection but has not yet disclosed the results of those exploratory protein analyses or demonstrated that the approach can reliably predict disease flares.
The research addresses a longstanding challenge in autoimmune disease investigation: symptoms and biological activity can change between scheduled clinical appointments. Conventional studies may collect blood samples at predetermined intervals that do not coincide with the onset or resolution of an inflammatory episode. Evidation is investigating whether decentralised, event-triggered sampling can provide a more detailed picture of these changes while allowing participants to remain in their everyday environments.
Why are rheumatoid arthritis flares difficult to capture through conventional clinical studies?
Rheumatoid arthritis is a chronic inflammatory autoimmune condition characterised by periods of varying disease activity. Patients may experience episodes of worsening joint pain, swelling, stiffness and functional impairment, followed by periods of improvement. The timing, duration and severity of these episodes can differ substantially between individuals.
Clinical research traditionally relies on scheduled visits to collect biological samples and assess disease activity. These visits provide useful information, but they may not coincide with periods when a participant’s symptoms are changing rapidly. As a result, researchers can miss molecular changes occurring around the onset or recovery phase of a flare.
This limitation is important for biomarker research because biological processes may evolve over shorter periods than conventional study schedules can capture. A blood sample obtained several weeks after a symptom episode may provide a different picture from one collected during the early stages of worsening disease. Repeated measurements at carefully selected times could therefore help investigators examine the relationship between molecular activity and clinical symptoms.
However, capturing more frequent information is not automatically equivalent to obtaining more clinically meaningful evidence. Researchers must determine whether the reported flare represents a genuine change in inflammatory disease activity, how consistently participants describe their symptoms and whether biological measurements correspond to the same event. Changes in pain or fatigue can also arise from factors other than autoimmune inflammation.
Evidation’s approach attempts to improve the timing of biological sampling by using participant reports to identify relevant periods. This may increase the likelihood of capturing dynamic changes that would otherwise be missed. The scientific value will depend on whether the collected samples and accompanying clinical information are sufficiently reliable to support meaningful comparisons.
How does the PACE study combine flare-triggered blood sampling with digital health data?
The PACE pilot uses a decentralised research model in which participants contribute information remotely rather than relying entirely on scheduled visits to a clinical research site. Daily symptom assessments help identify potential disease flares and inform the timing of blood collection. The resulting biological samples can then be analysed alongside information about symptoms and other health-related measurements.
The study is designed to examine three broad disease states: baseline, flare and recovery. This structure allows researchers to compare measurements within the same individual across different periods. Such comparisons may be informative because a participant’s baseline biological characteristics can differ substantially from those of another person with rheumatoid arthritis.
Evidation plans to analyse 251 proteins associated with inflammation, seeking patterns that may accompany changes in disease activity. The pilot also includes baseline genetic sampling, longitudinal clinical information and wearable observations. Combining these data sources may provide a richer research dataset than any single measurement method used independently.
Wearable devices can generate information about physiological and behavioural characteristics such as activity, sleep and selected cardiovascular measurements, depending on the device and its capabilities. These observations may help researchers examine how daily functioning changes during reported symptom episodes. However, wearable measurements do not directly establish the biological cause of a flare or replace validated assessments of inflammatory disease activity.
The pilot’s primary purpose is feasibility. Evidation is testing whether participants can provide repeated symptom information, whether remote blood collection can be coordinated with reported events and whether the resulting datasets can be linked for analysis. These operational questions must be answered before the approach can be considered suitable for substantially larger biological investigations.
The company describes the study as a first-of-its-kind combination of fully decentralised, symptom-triggered molecular sampling with longitudinal information in rheumatoid arthritis. That description reflects the company’s positioning of the research model, rather than independently establishing that no comparable study has used related methods. The measurable milestone is completion of the pilot’s planned monitoring and biospecimen collection.
What can 1,300 daily symptom assessments establish in a 29-person pilot?
The collection of more than 1,300 daily symptom assessments over approximately 60 days demonstrates that a small participant group was able to contribute repeated information during the study. This is operationally relevant because decentralised research depends on participants maintaining engagement outside conventional clinical visits. Repeated reporting can provide a more detailed picture of symptom variation than isolated retrospective questionnaires.
Nevertheless, the number of assessments should not be confused with the number of independent study participants. Multiple observations from the same individual are correlated, meaning 1,300 symptom reports do not provide the statistical independence of a study involving 1,300 different patients. The effective amount of information available for a particular analysis depends on the number of participants, the number of relevant flare episodes and the completeness of the associated biological sampling.
The distribution of assessments also matters. A participant who provides frequent reports without experiencing a flare may contribute useful baseline information but relatively little data about flare-associated biological changes. Conversely, a participant experiencing several episodes may contribute multiple observations that require appropriate statistical handling.
The company has not disclosed the complete distribution of captured flare episodes, the number of blood samples obtained at each disease state or the proportion of planned collections completed successfully. Those details will be necessary to evaluate whether the approach produces sufficiently complete datasets for reliable molecular comparisons. A successful feasibility study should demonstrate not only participation but also dependable alignment between reported events and biological sampling.
The small population also limits the diversity of clinical characteristics represented. Rheumatoid arthritis patients may differ in disease duration, medication use, baseline inflammatory activity and other health conditions. Such factors can influence both symptoms and protein measurements, complicating the interpretation of a limited pilot dataset.
PACE can therefore support decisions about study design and operational scalability, but it is not sufficiently powered to validate a generalisable rheumatoid arthritis biomarker signature. That would require larger populations, appropriate clinical reference measures and independent confirmation of the resulting findings.
Why could within-person proteomics provide a different view of autoimmune disease activity?
Traditional biomarker studies frequently compare measurements between groups of patients, such as individuals with active disease and those with relatively well-controlled symptoms. These comparisons can identify biological differences, but they may also be influenced by variation in age, medication exposure, disease history and other patient characteristics. Longitudinal within-person research offers a complementary approach.
By collecting samples during baseline, flare and recovery periods, researchers can examine how an individual’s molecular profile changes over time. This may help distinguish relatively stable personal characteristics from temporary biological changes associated with a reported disease episode. The approach is particularly relevant where the timing of symptoms varies unpredictably.
Proteomics allows researchers to measure multiple proteins simultaneously, potentially identifying patterns that reflect different biological pathways. In rheumatoid arthritis, inflammatory signalling involves numerous molecules and cell types, making a broad panel potentially useful for exploring disease mechanisms. However, measuring a large number of proteins also creates statistical challenges.
When 251 proteins are evaluated, some apparent changes may arise by chance, particularly in a small exploratory study. Appropriate analytical methods are needed to account for repeated measurements, multiple comparisons and variation in sample timing. The resulting patterns must also be assessed for biological plausibility and reproducibility.
Medication changes represent another important consideration. Patients experiencing worsening rheumatoid arthritis symptoms may modify treatment under clinical supervision, and those changes can affect inflammatory protein levels. Researchers therefore need sufficient treatment information to distinguish medication-related effects from biological changes associated with disease activity.
The strongest potential outcome would be identifying molecular patterns that repeatedly accompany or precede clinically meaningful flare episodes. However, such findings would initially be hypothesis-generating. Establishing a predictive biomarker would require independent validation and demonstration of performance in populations not used to discover the original signal.
How does Evidation’s larger autoimmune cohort support future research?
PACE builds on an autoimmune research cohort that Evidation launched in November 2025. The company reports that it has ongoing relationships with more than 100,000 individuals diagnosed with autoimmune conditions, creating a broader population from which participants may be recruited for longitudinal research. As of October 2026, more than 4,400 individuals were participating in its autoimmune cohort.
The cohort includes people with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Sjögren’s disease, inflammatory bowel disease and multiple sclerosis. These conditions share aspects of immune dysregulation but differ in their clinical manifestations, diagnostic criteria and underlying biological processes. A method developed in rheumatoid arthritis cannot automatically be assumed to identify equivalent flare biology in the other diseases.
More than 3,200 participants had completed at least 30 daily flare assessments, while over 1,500 had reported at least one qualifying flare episode. Evidation also reported wearable observations surrounding flare episodes for more than 1,200 participants, with a subset contributing linked electronic health records. These figures indicate a substantial amount of longitudinal data collection activity beyond the initial PACE pilot.
The larger cohort may help address recruitment and study timing challenges in future research. Rather than enrolling participants for a fixed short-term observation period without knowing whether a flare will occur, researchers may be able to identify individuals with relevant symptom histories and invite them into more targeted investigations. This could improve the feasibility of collecting biological samples around disease events.
However, the cohort’s size does not establish that its members are representative of the broader autoimmune population. Participation requires willingness and ability to engage with digital research tools, which may introduce selection bias. Differences in access to wearable devices, digital literacy and healthcare services could also affect the types of individuals contributing data.
Future studies will therefore need to assess population diversity and the suitability of their recruitment methods. A large digital cohort offers important operational advantages, but generalisability depends on how participants are selected and how effectively the resulting data capture relevant patient characteristics.
Could flare-triggered proteomics improve drug development and biomarker discovery?
Pharmaceutical developers increasingly seek biomarkers that can help define disease activity, identify appropriate patient populations and assess treatment responses. Autoimmune conditions are particularly challenging because symptoms and biological activity may fluctuate, while treatment effects can vary between patients. A dataset connecting molecular measurements with the timing of symptom changes could provide additional information for exploratory research.
Flare-triggered sampling may help researchers identify proteins or molecular pathways associated with worsening disease. These observations could contribute to understanding disease mechanisms or generate hypotheses about potential therapeutic targets. However, association with a flare does not establish that a protein causes the episode or that modifying it would provide clinical benefit.
The method could also help inform the design of future clinical studies. If certain biological changes consistently occur before or during flare episodes, investigators might use that knowledge to select sampling windows or develop exploratory endpoints. Such applications would require appropriate validation before they could support important treatment decisions.
Digital health measurements may provide complementary context about functional consequences. Activity or sleep changes, for example, could be examined alongside symptom reports and molecular data. Nevertheless, these measurements can be influenced by many factors unrelated to autoimmune disease, making careful interpretation essential.
The commercial opportunity for Evidation lies in providing pharmaceutical and research partners with access to longitudinal, participant-generated datasets and associated study capabilities. Such services could support observational research, exploratory biomarker programmes and evidence generation. However, the PACE announcement does not disclose new customer contracts, commercial revenue or validated drug discovery outputs resulting from the pilot.
The company will therefore need to demonstrate that the additional complexity of event-triggered sampling produces information that conventional approaches cannot obtain as effectively. A larger dataset is not necessarily more valuable unless its biological measurements are reliable, its clinical context is sufficiently detailed and its analytical outputs can be reproduced.
What privacy and data-quality challenges accompany decentralised molecular research?
PACE combines several categories of sensitive participant information, including symptom histories, biological samples, genetic information, wearable measurements and clinical records. Linking these datasets creates opportunities for more detailed research, but it also increases the importance of consent, data governance and appropriate access controls. Participants must understand how their information and samples are used and what future research activities their participation may support.
De-identification and secure data handling are important safeguards, although combining multiple datasets can increase the complexity of protecting privacy. Genetic information and detailed longitudinal records can be particularly sensitive. Research organisations therefore need appropriate technical, contractual and governance measures for the information being collected.
Data quality is another major consideration. Wearable devices may differ in their measurement characteristics, while patient-reported symptoms can be influenced by personal interpretation and reporting habits. Biological samples collected at home introduce additional requirements involving sample collection, stability, transport and laboratory processing.
The interval between a reported flare and collection of a blood sample could materially influence molecular measurements. A sample obtained shortly after symptom onset may differ from one collected several days later, even if both are classified as flare-associated. Accurate timestamps and consistent collection procedures are therefore important.
Researchers must also account for missing observations. Participants may be less able to complete assessments or collect samples when symptoms are severe, potentially creating gaps precisely when biological information would be most valuable. The resulting patterns of missing data require consideration during analysis.
These issues do not undermine the rationale for decentralised research, but they define the evidence needed to establish its scientific reliability. The feasibility of linking data streams must eventually be accompanied by evidence that the resulting measurements are accurate, sufficiently complete and suitable for the intended analyses.
What will determine whether Evidation’s PACE platform can scale beyond a pilot?
Evidation expects to share further information about its autoimmune research platform during London Life Sciences Week on November 17, 2026. The scheduled presentation provides an opportunity to discuss the broader research strategy, although it should not be interpreted as confirmation that the pilot has already identified clinically validated biomarkers. The complete exploratory analyses remain a future evidence milestone.
The next meaningful results will involve the feasibility of collecting appropriately timed samples and the patterns identified across the 251 inflammation-associated proteins. Researchers will need to report how many relevant biological observations were obtained, whether they corresponded to documented symptom states and how consistently the resulting signals appeared within and between participants. Those details will determine the strength of the pilot’s scientific contribution.
If the approach proves reproducible, larger studies could examine whether similar patterns occur across different autoimmune conditions or treatment populations. Such expansion would require disease-specific definitions of flares and appropriate clinical validation. The presence of shared inflammatory pathways does not guarantee that one molecular signature will perform similarly across rheumatoid arthritis, inflammatory bowel disease or multiple sclerosis.
Evidation has demonstrated that a small group of participants can contribute repeated symptom information and remotely coordinated samples during a short research period. The more demanding task is establishing that this approach produces reliable, clinically interpretable molecular evidence. Its long-term value will depend on moving from successful data collection towards independently reproducible biological findings that meaningfully improve autoimmune research and drug development.
